$80M for New Fabrazyme Facility

Sanofi company Genzyme is investing $80 million to build a new downstream processing facility for Fabrazyme (agalsidase beta). The new plant, which will be located adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, Massachusetts, will significantly expand purification capacity to support anticipated growth in global demand over the coming years. Read the full story